[Strategies for management of axillary lymph nodes in breast cancer. Point of view of the Institut Bergonié. ].
Sentinel lymph node biopsy in breast cancer has changed pathology management of axillary lymph nodes by pathologists, but there is still no consensus either for serial sectioning nor for immunohistochemistry. We analyze: 1) data in the literature about the prognostic significance of micrometastases (pNlmi) and immunohistochemically detected infiltrating tumor cells (pN0(i+) in axillary lymph nodes. 2) management strategies at the Bergonié Institute and by other teams for axillary lymph nodes and sentinel lymph nodes. 3) questions and controversies on sentinel lymph node management and recommendations of the five main reference groups.
de Mascarel
Isabelle
I
Département de Pathologie, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux Cedex.
MacGrogan
Gaëtan
G
D000047:Academies and Institutes / Q000706:statistics & numerical data; D001365:Axilla; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000601:surgery; D002277:Carcinoma / Q000473:pathology* / Q000556:secondary / Q000601:surgery; D019090:Case Management; D005260:Female; D005602:France; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008867:Microtomy / Q000379:methods; D009367:Neoplasm Staging / Q000379:methods; D011379:Prognosis; D021701:Sentinel Lymph Node Biopsy; D015996:Survival Rate
D014408:Biomarkers, Tumor